3 Global Stocks Estimated To Be Trading Below Intrinsic Value
In the current global market landscape, major U.S. stock indexes have shown mixed performances amid signs of a cooling labor market and subdued consumer confidence, while European markets have been buoyed by lower-than-expected inflation rates. As investors navigate these conditions, identifying stocks that are potentially trading below their intrinsic value can offer opportunities for those looking to capitalize on undervalued assets in an environment where economic indicators remain varied.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| VINA TECHLtd (KOSDAQ:A126340) | ₩71800.00 | ₩139731.32 | 48.6% |
| Netcompany Group (CPSE:NETC) | DKK320.20 | DKK637.29 | 49.8% |
| Micro Systemation (OM:MSAB B) | SEK81.80 | SEK159.17 | 48.6% |
| Laopu Gold (SEHK:6181) | HK$383.00 | HK$746.24 | 48.7% |
| Koskisen Oyj (HLSE:KOSKI) | €8.84 | €17.54 | 49.6% |
| F-Secure Oyj (HLSE:FSECURE) | €1.994 | €3.90 | 48.9% |
| DIO (KOSDAQ:A039840) | ₩12830.00 | ₩25424.61 | 49.5% |
| COVER (TSE:5253) | ¥1603.00 | ¥3137.67 | 48.9% |
| Appear (OB:APR) | NOK47.50 | NOK94.25 | 49.6% |
| Addvalue Technologies (SGX:A31) | SGD0.133 | SGD0.26 | 48.9% |
Let's dive into some prime choices out of the screener.
Gentera. de (BMV:GENTERA *)
Overview: Gentera, S.A.B. de C.V. operates in Mexico and Peru offering a range of financial products and services, with a market cap of MX$61.99 billion.
Operations: The company generates revenue through its diverse portfolio of financial products and services offered across Mexico and Peru.
Estimated Discount To Fair Value: 25.3%
Gentera is trading at MX$39.25, below its estimated future cash flow value of MX$52.53, suggesting it may be undervalued based on cash flows. Despite a high level of bad loans at 4.1%, the company shows strong earnings growth, with a 27.5% increase over the past year and forecasted annual growth of 11.1%. However, its share price has been highly volatile recently and relies heavily on higher-risk funding sources.
- Our growth report here indicates Gentera. de may be poised for an improving outlook.
- Unlock comprehensive insights into our analysis of Gentera. de stock in this financial health report.
CSPC Innovation Pharmaceutical (SZSE:300765)
Overview: CSPC Innovation Pharmaceutical Co., Ltd. is involved in the research and development, production, and sales of biopharmaceuticals, functional foods, and raw materials both in China and internationally, with a market cap of CN¥50.66 billion.
Operations: The company generates revenue through its activities in the research, development, production, and sales of biopharmaceuticals, functional foods, and raw materials across domestic and international markets.
Estimated Discount To Fair Value: 47.9%
CSPC Innovation Pharmaceutical is trading at CN¥38.7, significantly below its estimated future cash flow value of CN¥74.24, indicating potential undervaluation based on cash flows. Despite a net loss of CN¥93.85 million in Q1 2026, revenue grew to CN¥664.65 million from the previous year's CN¥471.97 million, with forecasts predicting profitability and above-market growth over the next three years. Recent board changes and bylaw amendments may influence strategic direction positively.
- The analysis detailed in our CSPC Innovation Pharmaceutical growth report hints at robust future financial performance.
- Get an in-depth perspective on CSPC Innovation Pharmaceutical's balance sheet by reading our health report here.
Aucnet (TSE:3964)
Overview: Aucnet Inc. is a circular market design company involved in online auctions and distribution of goods such as flowers, used motorcycles, and medical equipment in Japan, with a market cap of ¥127.92 billion.
Operations: The company's revenue segments include Lifestyle Product at ¥47.08 billion and Mobility & Energy at ¥16.44 billion.
Estimated Discount To Fair Value: 37.3%
Aucnet is trading at ¥1,392, significantly below its estimated future cash flow value of ¥2,218.49, suggesting potential undervaluation. The company raised its earnings guidance for 2026 with expected net sales of ¥72 billion and operating profit of ¥11.5 billion. Despite a volatile share price recently, Aucnet's revenue and earnings are forecast to grow faster than the Japanese market average over the coming years.
- In light of our recent growth report, it seems possible that Aucnet's financial performance will exceed current levels.
- Navigate through the intricacies of Aucnet with our comprehensive financial health report here.
Where To Now?
- Click here to access our complete index of 385 Undervalued Global Stocks Based On Cash Flows.
- Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
- Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.
Searching for a Fresh Perspective?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com